Aclatonium Napadisilate

萘二磺乙乳胆铵

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameAclatonium Napadisilate
Drug Alias Namenapadisilato de aclatonio萘二磺酸乙乳胆胺aclatonii napadisilas阿克拉胆碱萘二磺酸盐napadisilate d'aclatonium +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMuscarinic acetylcholine receptor agonists
TargetsMuscarinic acetylcholine receptor
Therapy Area/IndicationsGastrointestinal motility disordersFeeding and Eating DisordersVomiting +[6] 
Global Approved IndicationsGastrointestinal motility disorders
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date1981/01/01
Country/TerritoryMainland ChinaJapan
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesFujifilm Toyama Chemical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesFujifilm Toyama Chemical Co LtdYangtze River Pharmaceutical (Group) Co LtdNanjing Huawe Medicine Technology Group Co Ltd
Inactive CompaniesN/A
Active IndicationsGastrointestinal motility disordersFeeding and Eating DisordersVomiting +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeA03FA
Related LinksKEGG